Biomarker testing service

This application note presents the development of a robust, semi-quantitative LC-MS/MS method to detect pepsin in tracheal aspirate samples for pepsin, and details issues encountered during development and their solutions.

A gastric reflux event (GRE) is defined as the passing of the gastroduodenal contents into the oesophagus and causing damage to the oesophagal mucosa. Monitoring GREs can aid clinical studies for drug development and inform treatment regimes in the clinic to minimise GRE occurrence, which can dramatically improve quality of life. This application note presents the development of a robust, semi-quantitative LC-MS/MS method to detect pepsin in tracheal aspirate using a Waters Acquity hyphenated to a Waters Xevo TQS.

Analysis of plasma samples from gastrectomy patients for glucagon demonstrated the improved specificity of LC-MS for peptide biomarker quantitation compared to traditional immunoassay approaches.

This white paper highlights a potential application for LGCs Biomarker Testing Service. It discusses utilizing biomarkers in the study of metabolic syndrome, which leads to an increased risk of Cardiovascular Disease and Type 2 Diabetes.

This white paper highlights a potential application for LGCs Biomarker Testing Service, the monitoring of Chronic Obstructive Pulmonary Disease (COPD). The analysis of disease progression and treatment response in COPD is reliant on the triangulation of biomarkers from three sub-pathologies.

This poster offers an introduction to the Singulex Erenna immunoassay system in comparison to standard ECL and ELISA methods. It describes a validation methods using IL-6 an important biomarker in many inflammatory diseases.

Watch this video to learn about the immunoassay techniques used to analyze samples from preclinical and clinical trials to screen for biopharmaceutical drugs, immunogenicity and analyze biomarkers. Robin Longdin, Sector Manager of the Biologics department within Drug Development Services at LGC, discusses how particular technologies have enabled them to analyze low abundant samples and achieve better results than conventional immunoassay techniques.

Dr Catarina Horro Pita, Principal Scientist in the Bioanalysis department within Drug Development Services at LGC, explains how the department is improving the analysis of small molecule biomarkers using LC/MS/MS. Learn how Dr Horro Pita aims to ensure scientific quality throughout method development, validation and sample analysis and works with clients to overcome challenges. Hear how these developments in biomarker analysis will improve early phase decision making.

James Howard, Scientist, Bioanalytical Sciences, Drug Development Services at LGC, explains how higher sensitivity in peptide bioanalysis is achieved through supercharging reagent, m-NBA (meta nitrobenzyl alcohol). Watch this video to find out how LGC develop LC-MS methods to overcome the challenges that come with the requirement of high sensitivity.

Learn about the expansion plans at LGC Group's Fordham operation. With brand new facilities for cell culture, flow cytometry, Singulex and molecular biology, the global life sciences measurement and testing company is expanding its services portfolio at the site near Cambridge, UK.

Specific cross functional expertise in impurity analysis and contamination investigations

Discover how LGC is overcoming the challenges of analyzing peptides with LC-MS

Learn how the Bioanalysis Department at LGC is implementing LC-MS to improve services

Find out how new immunoassay techniques are being used to analyze samples from preclinical and clinical trials